Evolus
EOLS
Market cap $885M

13.97 USD

-0.24

1.69%

At close Jan 31, 4:00 PM EST

After hours

13.97

+0.00

0.00%

1 day

-1.69%

5 days

-1.83%

1 month

26.54%

3 months

-14.40%

6 months

12.48%

Year to date

25.74%

1 year

10.09%

5 years

36.56%

10 years

21.48%

About: Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Employees: 322

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,831 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more call options, than puts

Call options by funds: $2.55M | Put options by funds: $851K

48% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 21

33% more capital invested

Capital invested by funds: $616M [Q2] → $817M (+$201M) [Q3]

28% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 43

5% more funds holding

Funds holding: 156 [Q2] → 164 (+8) [Q3]

10.67% less ownership

Funds ownership: 90.66% [Q2] → 79.99% (-10.67%) [Q3]

14% less funds holding in top 10

Funds holding in top 10: 7 [Q2] → 6 (-1) [Q3]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$22

57%

upside

Avg. target

$24

69%

upside

High target

$27

93%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Barclays Balaji Prasad 44% 1-year accuracy 18 / 41 met price target	57%upside $22	Overweight Maintained	27 Jan 2025
HC Wainwright & Co. Douglas Tsao 35% 1-year accuracy 61 / 175 met price target	93%upside $27	Buy Reiterated	22 Jan 2025
Needham Serge Belanger 46% 1-year accuracy 60 / 130 met price target	57%upside $22	Buy Reiterated	21 Jan 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about EOLS published over the past 30 days

Zacks Investment Research

Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?

Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?

Investors Business Daily

Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why

Shares of Evolus made a doubly bullish move Tuesday on a strong preliminary fourth-quarter report and guidance for 2025. The post Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why appeared first on Investor's Business Daily.

Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2024. The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company's 2024 financial results is completed a.

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in January of an aggregate of 15,332 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant.

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25

I previously rated Evolus, Inc. stock a “Buy” due to its litigation settlement with AbbVie, strong revenue targets, and promising product performance. Despite positive updates, Evolus stock fell sharply, possibly due to market unpredictability and sector instability. Evolus' ambitious revenue targets and profitability projections face skepticism, but strong product performance and brand loyalty offer optimism.

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25

The Motley Fool

2 Growth Stocks That Will Bounce Back Big in 2025

In today's video, I will be talking about two growth stocks that are down over 40% this year but could provide investors with plenty of upside in 2025. Watch the short video to learn more, consider subscribing, and click the special offer link below.

2 Growth Stocks That Will Bounce Back Big in 2025

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November non-qualified stock options to purchase an aggregate of 9,872 shares of Evolus and an aggregate of 16,596 restricted stock units (RSUs) of the company's common stock to 9 newly hired non-executive employees of the company (the “November Grants”). The Company also is reporting the grant in Decemb.

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher

Evolus (EOLS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher

Zacks Investment Research

Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)

Evolus (EOLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)

Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript

Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript

Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™